THE ROLE OF PEROXISOME PROLIFERATION RECEPTORS PPARΑ IN THE LIPID-LOWERING EFFECT OF BETULIN IN NONALCOHOLIC FATTY LIVER DISEASE IN RATS
Abstract
Background. Non-alcoholic fatty liver disease (NAFLD) is a significant biomedical challenge. The triterpenoid botulin is one of promising therapeutic agents for NAFLD treatment. It is hypothesized that betulin exerts its lipid-lowering effects through the activation of peroxisome proliferator-activated receptors (PPAR), specifically PPARα. Objective. The aim of this study was to assess the role of PPARα in mediating the lipid-lowering effects of betulin in a rat model of NAFLD. Materials and methods. The study was performed on Wistar rats utilizing contemporary biochemical and molecular biological techniques. Results. Administration of betulin (100 mg/kg/day for 28 days) to rats with NAFLD resulted in significant hepatoprotective and lipid-lowering effects. Betulin prevented the development of hepatomegaly and normalized the lipid profiles in both the blood serum and liver of NAFLD rats by increasing PPARα expression levels in the liver tissue. The administration of the PPARα antagonist GW6471 to betulin-treated NAFLD-rats reduced the betulin-induced increase in PPARα expression and inhibited hypolipidemic effect of betulin. Conclusion. The lipid-lowering effect of betulin in NAFLD is attributed to the increased expression levels of PPARα in the liver.
References
Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):32-42. https://doi.org/10.3350/cmh.2022.0365.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https://doi.org/10.1097/HEP.0000000000000323.
Buko V, Kuzmitskaya I, Kirko S, Belonovskaya E, Naruta E, Lukivskaya O, Shlyahtun A, Ilyich T, Zakreska A, Zavodnik I. Betulin attenuated liver damage by prevention of hepatic mitochondrial dysfunction in rats with alcoholic steatohepatitis. Physiol Int. 2019;106(4):323-334. https://doi.org/10.1556/2060.106.2019.26.
Buko V, Zavodnik I, Palecz B, Stepniak A, Kirko S, Shlyahtun A, Misiuk W, Belonovskaya E, Lukivskaya O, Naruta E, Kuzmitskaya I, Ilyich T, Erdenebayar B, Rakhmadiyeva S. Betulin/2-hydroxypropyl-β-cyclodextrin inclusion complex: Physicochemical characterization and hepatoprotective activity. J Mol Liq. 2020;309:113118. https://doi.org/10.1016/j.molliq.2020.113118.
Adepoju FO, Duru KC, Li E, Kovaleva EG, Tsurkan MV. Pharmacological potential of betulin as a multitarget compound. Biomolecules. 2023;13(7):1105. https://doi.org/10.3390/biom13071105.
Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, Song BL. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 2011;13(1):44-56. https://doi.org/10.1016/j.cmet.2010.12.004.
Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010:612089. https://doi.org/10.1155/2010/612089.
Shlyahtun AH, Maksimchik YuZ, Raduta EF, Sutsko IP. Vlijanie betulina na aktivnost karnitin-palmitoiltransferazy 1 tipa v mitohondrijah pecheni krys [Effect of betulin on carnitine-palmitoyltransferase-1 activity in rats liver]. Vestnik Polesskogo gosudarstvennogo universiteta. Serija prirodovedcheskih nauk [Bulletin of Palesky state university. Series in Natural Sciences]. 2022;2:57-63. edn: WEPMXG. (Russian).
Shlyahtun AH, Maksimchik YuZ, Raduta EF, Polubok VCh, Buksha EV, Bogdevich EV, Sutsko IP, Gurinovich VA, Astrovski AA. Vlijanie triterpenoida betulina na jekspressiju karnitinpalmitoiltransferazy v pecheni krys pri nealkogolnoj zhirovoj bolezni pecheni s priznakami steatogepatita [Effect of triterpenoid betulin on expression of carnitine palmitoyltransferase in liver of rats with non-alcoholic fatty liver disease with signs of steatohepatitis]. Vestnik Polesskogo gosudarstvennogo universiteta. Serija prirodovedcheskih nauk [Bulletin of Palesky State University. Series in Natural Sciences]. 2024;1:46-55. (Russian).
Semenenya IN, Shlyahtun AH, Raduta HF. Rol receptorov, aktivirujushhih proliferaciju peroksisom, v kontrole alkogolnoj zavisimosti i lechenii soputstvujushhih zabolevanij pecheni [Role of peroxisome proliferator-activated receptors in the control of alcohol dependence and concomitant liver pathology]. Izvestija Nacionalnoj akademii nauk Belarusi. Serija medicinskih nauk [Proceedings of the National Academy of Sciences of Belarus. Medical series]. 2019;16(2):244-256. https://doi.org/10.29235/1814-6023-2019-16-2-244-256. https://elibrary.ru/akdunt. (Russian).
Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, Gorrell MD, Yue DK, Twigg SM. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 2011;55(2):435-44. https://doi.org/10.1016/j.jhep.2010.10.039.
Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR alpha. Nature. 2002;415(6873):813-7. https://doi.org/10.1038/415813a.
1.png)
